The potential for supply constraints also concerns industry analysts. For example, McKinsey analysts have warned that limited AAV vector capacity could delay the commercialization of new gene therapies, particularly those intended for larger patient populations.
Last March, a McKinsey article stated, “The majority of early viral-vector-based therapeutics were developed within the context of rare diseases. [Only small] quantities of viral vectors were required, particularly as most therapies were still in the clinical stage of development. Now, with the shift beyond ultrarare indications, viral vector manufacturing requires rapid expansion to be able to address these diseases in the commercial space.”
Leave a reply